RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Pathology of Peripheral Neuroblastic Tumors

        Hiroyuki Shimada,Hideki Sano,Florette K. Hazard 대한소아혈액종양학회 2020 Clinical Pediatric Hematology-Oncology Vol.27 No.2

        Peripheral neuroblastic tumors (pNTs including Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma) are biologically and clinically heterogeneous. In order to develop efficient clinical treatment protocols of this disease, patients are stratified into different risk groups based on the combination of so-called prognostic factors. In this review, the prognostic factors are classified as clinically defined (Clinical staging and Age at diagnosis), histopathologically defined [International Neuroblastoma Pathology Classification (INPC) distinguishing Favorable Histology (FH) Group and Unfavorable Histology (UH) Group] and genetically/molecularly defined [MYCN oncogene amplification, DNA index, Segmental chromosomal aberrations, ALK (Anaplastic Lymphoma Kinase) mutation/amplification and Abnormal maintenance/elongation of telomeres], are outlined. According to the Children’s Oncology Group (COG) Neuroblastoma studies, the survival rate of patients in low- or intermediate-risk group is more than 90%. In contrast, the survival rate of patients in the high-risk group remains less than 50% despite currently available high-intensity and multimodal therapy. As described in the genetically/molecularly defined prognostic factors, tumors in the high-risk group, majority of which are classified into the UH group according to the INPC, are molecularly heterogeneous. Based on the recent progress of precision medicine along with our correlative analyses between molecular alterations and their morphological manifestations, four subgroups; i.e., MYC subgroup, TERT subgroup, ALT subgroup and Null subgroup, are identified immunohistochemically in the UH group for future management of the patients with this unique d isease.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼